Australia Updates Biologics GMPs

The Therapeutic Goods Administration has revised 2,000 good manufacturing practice codes for biologic drugs, blood and tissue components and cellular therapy products. To maintain appropriate quality assurance, manufacturers must ensure the products — and their starting materials — are designed and developed in accordance with the new codes and that managerial responsibilities are clearly defined.
International Pharmaceutical Regulatory Monitor